Study on Thrombosis Therapy in German Cancer Patients

LEO Pharma76 enrolled

Overview

The study aims to document the flow of German patients with cancer and acute deep vein thrombosis from first visit to diagnosis and treatment, the applied diagnostic procedures, and therapy modalities.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Cancer Deep Vein Thrombosis Pulmonary Embolism

Interventions

no intervention is being madeOTHER

This is a Non-Interventional Study (NIS)

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * patient with cancer and acute deep vein thrombosis and/or pulmonary embolism Exclusion Criteria: * life expectancy less that 6 months * age less that 18 years

Locations (1)

Prof. Dr. Axel Matzdorff

Saarbrücken, Saarland, Germany

Outcomes

Primary Outcomes

treatment time on low molecular weight heparin

Time frame: 1 year

Secondary Outcomes

patient pathways

data collection on patient pathway: who is the referring physician, physician who diagnoses deep vein thrombosis (DVT)

Time frame: 1 year

risk factors for DVT

Time frame: 1 year

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.